| Document |
Document Title |
|
WO/2023/049295A1 |
Deuterated compounds are provided according to Formula (I): Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. These compounds are contemplated as useful for the prevention and treatment o...
|
|
WO/2022/231417A1 |
The present invention relates to an apparatus and process for the controlled and precise chemical cross-linking of a structure made of human collagen having variable mechanical, chemical and biological features, characterised in that it ...
|
|
WO/2022/225999A1 |
Provided herein are methods for treating, preventing, minimizing and/or substantially inhibiting inflammation associated with a respiratory virus such as COVID-19 and/or acute respiratory distress syndrome (ARDS), comprising administerin...
|
|
WO/2022/198191A1 |
The present disclosure relates to polycyclic (e.g., tetracyclic) androgen receptor (AR) modulators, synthetic methods for preparing such AR modulators, and methods of using such AR modulators to treat an androgen-dependent condition, suc...
|
|
WO/2021/262836A1 |
Provided herein is a compound of the Formula (I) or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3a, R4a, R4b, R5, R6, R7, R11a, R11b, R15a, R15b, R16,R17, R19, RX, RY, and t are defined herein. Also provided herein are...
|
|
WO/2021/252761A2 |
Disclosed herein are monomeric and oligomeric compound embodiments for use as contraceptive agents. Monomeric compound embodiments disclosed herein comprise substituents that facilitate the ability of the compounds to exhibit progestogen...
|
|
WO/2021/067089A1 |
The invention provides compositions containing isomerically pure forms of neurosteroids that permit preferential modulation of different subtypes of GABAA receptors, such as preferential modulation of α4β3δ GABAA receptors over α1β2...
|
|
WO/2020/132504A1 |
Provided herein is a compound of Formula (I) or pharmaceutically acceptable salt thereof, wherein R2a, R2b, R4a, R4b, R6, R7, R11a, R11b, R16, R17, R3, R5, R19 and RX are defined herein and wherein RY represents optionally substituted he...
|
|
WO/2020/051329A1 |
The present disclosure relates to stereodefined polycyclic (e.g., tetracyclic) compounds that contain quaternary centers at one or multiple ring fusions, synthetic methods for preparing such compounds, and methods of using such compounds...
|
|
WO/2020/020728A1 |
Disclosed are compounds of formula (I), wherein X, Y, Z are annular atoms comprised in a five-membered carbocyclic or heterocyclic ring, selected from the group consisting of CH, NH, N, O, S; saidcarbocyclic or heterocyclic ring being op...
|
|
WO/2019/154257A1 |
The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound of formula (I), a preparation method therefor, a pharmaceutical ...
|
|
WO/2019/154247A1 |
The present invention relates to steroid derivative regulators, a method for preparing the same, and uses thereof. Specifically, the present invention relates to a compound as shown in formula (I), a preparation method therefor, a pharma...
|
|
WO/2019/126741A1 |
Provided herein are compounds of Formula (I-I): and pharmaceutically acceptable salts thereof; wherein p, R1, R3a, R2a, R11a, R11b, R6a, and R6b are defined herein. Also provided herein are pharmaceutical compositions comprising a compou...
|
|
WO/2019/040879A1 |
Disclosed herein are methods of using immunomodulatory sterols as vaccine adjuvants. Accordingly, certain embodiments relates to pharmaceutical compositions containing at least one antigen and at least one immunomodulatory sterol; and, m...
|
|
WO/2018/232007A1 |
Potent soft corticosteroid pharmaceutical compositions comprising them and method for use as anti-inflammatory agents. Also, a method for softening fluticasone propionate and similar corticosteroids to arrive at potent but safer alternat...
|
|
WO/2017/172612A1 |
Assay methods for determining purity of a sample of a sterol are provided. These methods include providing an HPLC eluent including a sterol, other compounds related to the sterol and a mobile volatile phase; generating an aerosol of liq...
|
|
WO/2017/146440A1 |
The present invention relates to co-crystals of androstenone and vanillin, a method for preparing the same and a use of the same. The co-crystals of androstenone and vanillin of the present invention have a rigid lattice structure so as ...
|
|
WO/2016/154203A1 |
Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2. In one embodiment, a cytotoxic compound...
|
|
WO/2016/082789A1 |
Described herein are neuroactive steroids of the Formula (II) : or a pharmaceutically acceptable salt thereof; wherein A, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6 and ----- are as defined herein. Such compounds are envisioned, in certain...
|
|
WO/2016/054280A1 |
A method of preparing a thioic acid intermediate of fluticasone propionate includes: treating a 17β-[(N,N-dimethyl carbamoyl)thio]carbonyl compound in a solution including an alcohol and an alkali metal hydroxide, an alkaline-earth meta...
|
|
WO/2014/169833A9 |
Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof; wherein-, R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7are as defined herein. Such compounds are contemplate...
|
|
WO/2012/161559A2 |
The present invention relates to a use of a composition in the manufacture of a product for regulating a plurality of genes consisting of phosphoenolpyruvate carboxykinase-1, fructose-1,6-bisphosphatase, xenobiotic metabolism, low-densit...
|
|
WO/2012/160338A1 |
The present invention relates to a method of preparing an organic biologically active compound of formula (I), wherein R1, R2, R3, R4,. X1, X2 and X3 are as defined in the specification, to certain novel intermediates obtainable from suc...
|
|
WO/2012/099477A1 |
The invention relates to methods of localising biofunctional moieties (F) to surfaces and synthetic constructs of the general structure F-S-S' for use in such methods. F is the biofunctional moiety, S is a spacer covalently linking F to ...
|
|
WO/2012/011106A1 |
The present invention provides an improved process for the preparation of 17-desoxy corticosteroid derivatives in a single chemical step by reacting the 17-hydroxy starting material with an excess of Trimethylsilyl Iodide. The present in...
|
|
WO/2010/136940A1 |
This invention relates to novel glucocorticoid receptor agonists of formula (I) and to processes and intermediates for their preparation. The present invention also relates to pharmaceutical compositions containing these compounds, to th...
|
|
WO/2010/071772A2 |
The present invention relates to methods for synthesizing preferred membrane-binding elements, preferably cholesterylamine derivatives, including 3-amino-5-cholestene (3-cholesterylamine) and related 3-halides through i-steroid and retro...
|
|
WO/2009/108388A2 |
Provided herein are steroidal compounds that are androsta-5,7-dienes or a pregna-5,7-dienes and ultraviolet B (UVB) conversion products thereof which includes pharmaceutical compositions of the steroidal compounds. Also provided is a met...
|
|
WO/2008/133387A1 |
The present invention relates to a novel acyclic triterpenoid compound and a pharmaceutical composition comprising an Alpinia katsumadai extract or acyclic triterpenoid compound isolated therefrom. The Alpinia katsumadai extract or acycl...
|
|
WO/2007/147713A1 |
New aminoalkoxyimino derivatives at position 3 of substituted B- homoandrostanes and B-heteroandrostanes, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, ...
|
|
WO/2007/099548A2 |
11 β-hydroxyandrosta-4-ene-3-one, compound of formula (I), and physiologically acceptable salt thereof; wherein R4 represents moiety selected from a group consisting of (A), (B) and (C), with a proviso that when R4 represents moiety (C)...
|
|
WO/2007/057152A1 |
The present invention is directed to compounds of formula (I) wherein R1 represents C4-C7 branched chain alkyl, C3-C8 cycloalkyl optionally substituted by one or more groups independently selected from C1-C3 alkyl and methoxy, C4-C6 cycl...
|
|
WO2005077968B1 |
The present invention relates to novel compounds which are 7alpha-substituted 17-alkylene-16 alpha-hydroxy steroidal estrogens (see formula I). This invention specifically relates to estrogen derivatives which contain 7 alpha -substituen...
|
|
WO/2006/072600A1 |
The present invention is directed to compounds of formula (I): wherein R1 represents a 1,1-dimethylethyl group or a 1,1-dimethylpropyl group and physiologically acceptable solvates thereof, physiologically functional derivatives thereof,...
|
|
WO/2006/072599A2 |
The present invention is directed to compounds of formula (I): wherein R1 represents C4-C7 branched alkyl group, a bicycloalkyl group, or a C5-C6 cycloalkyl which optionally may be substituted with a C1-C4 alkyl group; R2 represents hydr...
|
|
WO/2006/032885A2 |
The present invention provides a compound comprising a steroidal ring system and an optional group R1 selected from any one of -OH, a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide gr...
|
|
WO/2005/030221A1 |
A drug exhibiting an excellent therapeutic efficacy for ageing macular degeneration. In particular, a therapeutic agent for ageing macular degeneration characterized in that a progesterone derivative of the general formula: (1) (wherein ...
|
|
WO/2005/030120A2 |
Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula (I) wherein the variables are defined in the specification.
|
|
WO2002042319A9 |
Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering derivatives of 2-methoxyestradiol of the general formula (I), wherein the variables are defined in the specification.
|
|
WO/2005/005451A1 |
A compound of formula (I): (I) wherein X represents O or S; R1 represents C1-6 alkyl, C3-8 cycloalkyl, C3-8 cycloalkylmethyl or C3-8 cycloalkenyl any of which optionally may be substituted by one or more methyl groups or halogen atoms or...
|
|
WO/2005/005452A1 |
A compound of formula (I): or a physiologically acceptable solvate thereof.
|
|
WO/2004/087731A1 |
A method for the conversion of steroidal 17β-carboxylic acids to c carbothioic acid and esters thereof such as fluticasone propionate.
|
|
WO/2004/039827A2 |
A compound of formula (I): whereinR1 represents C1-6 alkyl or C1-6 haloalkyl;X represents O or S;R2 represents C3-8 cycloalkyl which optionally may be substituted by one or more groups selected from C1-6 alkyl, oxo, or halogen n is an in...
|
|
WO2004011663A9 |
Disclosed is a new synthetic pathway for the production of precursors for the production of compounds having general formula (8,10,12). During said synthesis, compounds of general formal (4,B) are produced in a microbiological reaction. ...
|
|
WO/2004/009527A1 |
The subject invention provides novel HMG-CoA-reductase inhibitors. In a preferred embodiment, the HMG-CoA reductase inhibitors of the subject invention can be deactivated to a primary inactive metabolite by hydrolytic enzymes. Compounds ...
|
|
WO/2004/001369A2 |
The present invention provides a convenient process for the preparation of S-fluoromethyl 6a, 9a-difluoro-11b-hydroxy-16a-methyl-17a-propionyloxy-3-oxoand
rosta-1, 4-diene-17b-carbothioate, a compound of formula (1), comprising(a) treati...
|
|
WO/2003/082896A2 |
The process for the preparation of 6&agr -fluoro steroids, comprising the reaction of the corresponding 6β-fluoro steroids, or of 6&agr /6β isomeric mixtures with an organic base having a diazo iminic group, in a suitably selected orga...
|
|
WO/2003/072592A1 |
A compound of formula (I): wherein R1 represents C1−6 alkyl or C1−6 haloalkyl&semi R2 represents C3−8 cycloalkyl or C3−8 cycloalkenyl either of which may be optionally substituted by one or more groups selected from C1−6 alkyl,...
|
|
WO/2003/066026A1 |
There is provided according to the invention a pharmaceutical formulation comprising an aqueous carrier liquid having dissolved therein: (a) a glucocorticoid of formula (I), wherein R represents ethyl or a 5 membered heterocyclic aromati...
|
|
WO/2003/066032A1 |
There is provided a pharmaceutical aerosol formulation comprising (i) a compound of formula (I) or a solvate thereof as medicament, (ii) a liquified hydrofluoroalkane (HFA) gas as propellant; and characterised in that the compound of for...
|
